Two-Year Retrospective Economic Evaluation of Three Dual-Controller Therapies Used in the Treatment of Asthma
Authors:
- John C. O'DOnnellJOJohn C. O'DOnnell
- Lionel A. PintoLPLionel A. Pinto
- Douglas J. WienerDWDouglas J. Wiener
- Antonio P. LegorretaALAntonio P. Legorreta
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid TherapyChest, 2001
- Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μ g twice daily and budesonide 800 μ g twice daily in the treatment of adults and adolescents with asthmaRespiratory Medicine, 2000
- Salmeterol/fluticasone propionate combination therapy 50/250 μ g twice daily is more effective than budesonide 800 μ g twice daily in treating moderate to severe asthmaRespiratory Medicine, 2000
- Heterogeneity of variance in clinical data.Journal of Consulting and Clinical Psychology, 2000
- The Cost of Asthma in the Emergency Department and HospitalAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Comparison of inhaled salmeterol and oral zafirlukast in patients with asthmaJournal of Allergy and Clinical Immunology, 1999
- Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Developing a Tool for Analyzing Medical Care Utilization of Adult Asthma Patients in Indemnity and Managed Care Plans: Can an Episodes of Care Framework Be Used?American Journal of Medical Quality, 1998
- Geographic Variations in the Use of Services: Do They Have Any Clinical Significance?Health Affairs, 1984